Circulating biomarkers: Hitting the mark
Circulating biomarkers, a new frontier in cancer care, bring both hope and unease to the clinic. Rogel researchers are unraveling their nuances, advancing enabling technologies, advocating for patients and figuring out how to ethically integrate this technology into clinical care.
The Cancer Microbiome
Scientists are just starting to appreciate the many ways microbes influence the initiation, progression and treatment of cancer. It's known that some microbiomes, like Helicobacter pylori’s triggers chronic inflammation that contributes to stomach cancer. It's also known that maintaining a a healthy gut microbiome nurtures our immune system so that our immune cells can fight against cancer. Learn how the Rogel Cancer Center research members are studying these microbiomes to better understand how to prevent and treat the development of gastrointestinal cancers.
Harnessing the Immune System to Target Cancer
When Weiping Zou, M.D., PH.D., Charles B. De Nancrede Professor of Surgery, Immunology, Biology and Pathology at the University of Michigan, first started looking at cancer immunology, he was one of only a handful in the field who believed in the idea. Today, immunotherapy has revolutionized cancer treatment and become one of the most promising avenues in cancer research.